LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy
Mohammad Ezaz Al Mamun,Yu Zhang,Jin-Yuan Zhao,Dan-Dan Shen,Ting Guo,Yi-Chao Zheng,Li-Juan Zhao,Hong-Min Liu +7 more
5
TL;DR: This review examines how LSD1 modulates different cell behavior in TME and emphasizes the potential use of LSD1 inhibitors in combination with ICB therapy for future cancer research studies.
read more
Abstract: Abstract Dysregulation of various cells in the tumor microenvironment (TME) causes immunosuppressive functions and aggressive tumor growth. In combination with immune checkpoint blockade (ICB), epigenetic modification-targeted drugs are emerging as attractive cancer treatments. Lysine-specific demethylase 1 (LSD1) is a protein that modifies histone and non-histone proteins and is known to influence a wide variety of physiological processes. The dysfunction of LSD1 contributes to poor prognosis, poor patient survival, drug resistance, immunosuppression, etc., making it a potential epigenetic target for cancer therapy. This review examines how LSD1 modulates different cell behavior in TME and emphasizes the potential use of LSD1 inhibitors in combination with ICB therapy for future cancer research studies.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
Mengdan Xu,Shenglong Li +1 more
TL;DR: This review summarizes the therapeutic potential of PD-L1 inhibitors in leukemia, highlighting promising clinical outcomes and the need for personalized approaches and combination therapies to optimize treatment efficacy and address immune-related adverse events.
4
Targeting LSD1 in cancer: molecular elucidation and recent advances
Wenpeng Cai,Chu Xiao,Tao Fan,Ziqin Deng,Di Wang,Yixiao Liu,Chunxiang Li,Jié He +7 more
TL;DR: It is highlighted that LSD1 is a promising target for cancer treatment and the latest theoretical references for further understanding the research progress of oncology and epigenetics are provided, deepening the updated appreciation of epigenetics in cancer.
4
Target Ligand Separation and Identification of Isoforsythiaside as a Histone Lysine-Specific Demethylase 1 Covalent Inhibitor Against Breast Cancer Metastasis
Mengzhen Gu,Xiaoqing Xu,Xiaoping Wang,Li Wang,Yong‐Min Liang,Xiaoxian Hu,Lu Zhu,Zhenzhong Deng,Chao Han +8 more
TL;DR: Researchers identified isoforsythiaside as a novel covalent inhibitor of histone lysine-specific demethylase 1 (LSD1), blocking its activity and inhibiting breast cancer metastasis by targeting the LSD1 downstream signaling pathway.
2
Inhibition of LSD1 enhances T cells anti-tumor immunity by promoting TNFSF14 expression in gastric cancer
Xueqing Xie,Wei Lü,Qing-Ling Yin,Meijun Hou,Jingjing Tian,Xunsheng Chen,Zhang Yuanling,Lili Zeng,Jie Ding,Xueqing Xie,Wei Lü,Qing-Ling Yin,Meijun Hou,Jingjing Tian,Xunsheng Chen,Zhang Yuanling,Lili Zeng,Jie Ding +17 more
Overview and new insights of lysine-specific histone demethylase 1 in colorectal cancer: promoting epithelial-mesenchymal transition and stemness features of cancer stem cells
Jiang Chen,Tao Yang,Tianbao Xiao,Ziwei Wang,Fan He,Tian-tian Bao,Yibo Cao +6 more
TL;DR: Lysine-specific histone demethylase 1 (LSD1) is a promising target for CRC therapy, some LSD1 inhibitors are in the experimental stage by blocking its demethylase activity and may benefit CRC patients in the clinical treatment course in the future.
References
Epigenetic mechanisms regulating T-cell responses.
TL;DR: This review focuses on DNA methylation, histone modifications, and chromatin structure as important epigenetic mechanisms involved in controlling T‐cell responses in light of the development, activation, and differentiation of CD4+ T helper, regulatory T, and CD8+ T cells.
Inhibition of LSD1 in MDS progenitors restores differentiation of CD141 Hi conventional dendritic cells.
Pragya Srivastava,Stephanie L. Tzetzo,Eduardo Cortes Gomez,Kevin H. Eng,Sheila N.J. Sait,Joseph Kuechle,Prashant Singh,Kitty De Jong,Kyle Wiatrowski,Jennifer Peresie,Ava R. Dimitroff,Miranda L. Lynch,Jianmin Wang,Scott I. Abrams,Elizabeth A. Griffiths,Michael J. Nemeth +15 more
TL;DR: It is found that CD141 Hi cDCs are reduced in MDS bone marrow and based on the premise established in solid tumors, it is hypothesized that reduced numbers of CD141Hi c DCs are associated with inferior overall survival in M DS patients and data reveal a previously unrecognized element of the MDS immunologic milieu.
Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione.
TL;DR: It is found that scaffolding LSD1 inhibitors potently reduce oxidative phosphorylation and glycolysis ofNK cells, and higher doses induce mitochondrial reactive oxygen species and depletion of the antioxidant glutathione, which can fully ablate the lytic capacity of NK cells.
ZMYND8 mediated liquid condensates spatiotemporally decommission the latent super-enhancers during macrophage polarization.
Pan Jia,Xiang Li,Xuelei Wang,Liangjiao Yao,Yingying Xu,Yu Hu,Wenwen Xu,Zhe He,Qifan Zhao,Yicong Deng,Yi Zang,Meiyu Zhang,Yan Zhang,Jun Qin,Wei Lu +14 more
TL;DR: In this article, the authors show that the epigenetic reader ZMYND8 forms liquid compartments with NF-κB/p65 to silence latent superenhancers and restrict macrophage-mediated inflammation.
The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy
Huan Liu,Jing Wei,Na Sang,Xi Zhong,Xia Zhou,Xinyu Yang,Jing Zhang,Zeping Zuo,Yang Zhou,Shengyong Yang,Junrong Du,Yinglan Zhao +11 more
TL;DR: The finding identifies that ZY0511 inhibits DLBCL growth both in vitro and in vivo via the induction of apoptosis and autophagy, and LSD1 inhibitor might be a promising strategy for treatingDLBCL.